The general conclusions of these reports are that ximelagatran isn't inferior to plain therapy to the acute therapy of DVT and is exceptional to placebo for extended secondary avoidance of recurrent DVT and/or PE.In 2006, its producer AstraZeneca declared that it would not make an effort to sector ximelagatran following experiences of hepatotoxicit